论文部分内容阅读
肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)能选择性地诱导肿瘤细胞凋亡,因此作为抗肿瘤药物备受瞩目,现已进入II期临床试验,尽管有报道称部分肿瘤细胞对TRAIL耐药,导致治疗效果不如预期,但TRAIL用于肿瘤治疗的前景依旧被人们看好。通过对TRAIL耐药机理的研究将有助于寻找逆转肿瘤细胞耐药的靶点,并通过联合用药来调节相关的信号分子以获得更好的抗肿瘤效应。该文将介绍TRAIL及其介导的细胞凋亡通路并总结近年来TRAIL耐药机理及逆转其耐药方面的研究进展。
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis of tumor cells. Therefore, TRAIL has drawn much attention as an anti-tumor drug and has now entered Phase II clinical trials. It is reported that some tumor cells are resistant to TRAIL, leading to the treatment effect is not as expected, but the prospect of TRAIL for cancer treatment is still being optimistic. Through the study of TRAIL resistance mechanism will help to find the target of reversal of drug resistance in tumor cells, and through the combination of drugs to regulate the relevant signal molecules in order to obtain better anti-tumor effect. This article will introduce TRAIL and its pathways mediated by apoptosis and summarize the recent progress in TRAIL resistance and reversal of its drug resistance.